--- title: "Sunifiram (DM-235): Dosing & Vendor Prices — BodyHackGuide" description: "Sunifiram (DM-235): dosing protocols, mechanism & side effects. Compare 1 verified vendor prices." lang: en json-ld: | [ { "@context": "https://schema.org", "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "Home", "item": "https://www.bodyhackguide.co/" }, { "@type": "ListItem", "position": 2, "name": "Compounds", "item": "https://www.bodyhackguide.co/compare" }, { "@type": "ListItem", "position": 3, "name": "Sunifiram (DM-235)" } ] }, { "@context": "https://schema.org", "@type": "Product", "name": "Sunifiram (DM-235)", "description": "Sunifiram, also called DM-235, is a piperazine that came out of an academic medicinal chemistry program at the University of Florence, not out of a pharmaceutical company. It was first reported in 2000 as one of a series of acylpiperazines obtained by simplifying a bicyclic scaffold, and it stood out for potency: it prevented amnesia in the mouse passive avoidance test at doses about a thousand times lower than piracetam-like reference compounds (PMID: 11087574; PMID: 12070754). Despite the racetam-style name it is not a pyrrolidinone and is not structurally a racetam. The mechanism is not fully resolved. Binding studies found no affinity for the major central receptors or channels, yet sunifiram prevented amnesia induced by drugs acting on several different transmitter systems, including scopolamine, mecamylamine, baclofen and clonidine (PMID: 12070754; PMID: 16834757). Two glutamatergic actions have been documented. Sunifiram and its analog unifiram reversed amnesia induced by the AMPA receptor antagonist NBQX in mice and reversed kynurenic acid blockade of NMDA-mediated noradrenaline release in rat hippocampal slices, an effect abolished by NBQX (PMID: 14600801). Separately, in mouse hippocampal slices sunifiram enhanced long-term potentiation with a bell-shaped concentration-response curve peaking at 10 nanomolar; the enhancement was blocked by an antagonist of the glycine site of the NMDA receptor but not by an antagonist of the polyamine site, and involved protein kinase C alpha, Src family kinase and calcium/calmodulin-dependent protein kinase II (PMID: 23733502). Sunifiram also increased acetylcholine release in rat brain (PMID: 11087574). In disease-model animals, sunifiram improved spatial reference memory in the Y maze and short-term memory in novel object recognition in olfactory bulbectomized mice and restored hippocampal long-term potentiation, with those effects blocked by a glycine site inhibitor; it did not improve depressive behavior in the same animals (PMID: 23295391). There is no human data of any kind. No clinical trial, case series or pharmacokinetic study has been published, and searches of ClinicalTrials.gov return no records. The chemist who led the group that discovered sunifiram and unifiram wrote in 2015 that he had discovered by chance that dozens of websites were selling both compounds as cognitive enhancers for healthy people, even though only a few preclinical studies had been performed and their long-term toxicity was unknown, and that neither compound had been protected by a patent or taken forward by industry (PMID: 25831025). Sunifiram is not approved in any country, is not a controlled substance in the United States and has no established human dose, safety threshold or contraindication list. Everything sold is a research chemical. One frequently cited paper on sunifiram carbamate hybrids as dual acetylcholinesterase inhibitors and NMDA co-agonists was retracted by the journal in 2026 (PMID: 42565552), so any claim traced back to it should be treated as unsupported.", "url": "https://www.bodyhackguide.co/compound/sunifiram", "image": "https://www.bodyhackguide.co/og-image.png", "brand": { "@type": "Brand", "name": "Research Compound" }, "offers": { "@type": "AggregateOffer", "lowPrice": "59.99", "highPrice": "59.99", "priceCurrency": "USD", "offerCount": "1", "availability": "https://schema.org/InStock", "offers": [ { "@type": "Offer", "price": "59.99", "priceCurrency": "USD", "availability": "https://schema.org/InStock", "itemCondition": "https://schema.org/NewCondition", "url": "https://disguisedalpha.com/product/sunifram/?coupon=reddit", "seller": { "@type": "Organization", "name": "Disguised Alpha", "url": "https://disguisedalpha.com/?coupon=reddit" }, "name": "Sunifiram (DM-235) 600mg capsule" } ] } }, { "@context": "https://schema.org", "@type": "MedicalWebPage", "name": "Sunifiram (DM-235)", "description": "Sunifiram, also called DM-235, is a piperazine that came out of an academic medicinal chemistry program at the University of Florence, not out of a pharmaceutical company. It was first reported in 2000 as one of a series of acylpiperazines obtained by simplifying a bicyclic scaffold, and it stood out for potency: it prevented amnesia in the mouse passive avoidance test at doses about a thousand times lower than piracetam-like reference compounds (PMID: 11087574; PMID: 12070754). Despite the racetam-style name it is not a pyrrolidinone and is not structurally a racetam. The mechanism is not fully resolved. Binding studies found no affinity for the major central receptors or channels, yet sunifiram prevented amnesia induced by drugs acting on several different transmitter systems, including scopolamine, mecamylamine, baclofen and clonidine (PMID: 12070754; PMID: 16834757). Two glutamatergic actions have been documented. Sunifiram and its analog unifiram reversed amnesia induced by the AMPA receptor antagonist NBQX in mice and reversed kynurenic acid blockade of NMDA-mediated noradrenaline release in rat hippocampal slices, an effect abolished by NBQX (PMID: 14600801). Separately, in mouse hippocampal slices sunifiram enhanced long-term potentiation with a bell-shaped concentration-response curve peaking at 10 nanomolar; the enhancement was blocked by an antagonist of the glycine site of the NMDA receptor but not by an antagonist of the polyamine site, and involved protein kinase C alpha, Src family kinase and calcium/calmodulin-dependent protein kinase II (PMID: 23733502). Sunifiram also increased acetylcholine release in rat brain (PMID: 11087574). In disease-model animals, sunifiram improved spatial reference memory in the Y maze and short-term memory in novel object recognition in olfactory bulbectomized mice and restored hippocampal long-term potentiation, with those effects blocked by a glycine site inhibitor; it did not improve depressive behavior in the same animals (PMID: 23295391). There is no human data of any kind. No clinical trial, case series or pharmacokinetic study has been published, and searches of ClinicalTrials.gov return no records. The chemist who led the group that discovered sunifiram and unifiram wrote in 2015 that he had discovered by chance that dozens of websites were selling both compounds as cognitive enhancers for healthy people, even though only a few preclinical studies had been performed and their long-term toxicity was unknown, and that neither compound had been protected by a patent or taken forward by industry (PMID: 25831025). Sunifiram is not approved in any country, is not a controlled substance in the United States and has no established human dose, safety threshold or contraindication list. Everything sold is a research chemical. One frequently cited paper on sunifiram carbamate hybrids as dual acetylcholinesterase inhibitors and NMDA co-agonists was retracted by the journal in 2026 (PMID: 42565552), so any claim traced back to it should be treated as unsupported.", "lastReviewed": "2026-09-07T04:48:27.111Z", "url": "https://www.bodyhackguide.co/compound/sunifiram", "author": { "@type": "Person", "name": "BioChonch", "url": "https://www.bodyhackguide.co/about", "jobTitle": "Founder & Lead Researcher", "sameAs": [ "https://x.com/bodyhackguide", "https://reddit.com/r/BodyHackGuide", "https://reddit.com/r/BrainHackGuide", "https://reddit.com/r/Biohackingher" ], "worksFor": { "@type": "Organization", "name": "BodyHackGuide", "url": "https://www.bodyhackguide.co" } }, "reviewedBy": { "@type": "Person", "name": "BioChonch", "url": "https://www.bodyhackguide.co/about", "jobTitle": "Founder & Lead Researcher", "sameAs": [ "https://x.com/bodyhackguide", "https://reddit.com/r/BodyHackGuide", "https://reddit.com/r/BrainHackGuide", "https://reddit.com/r/Biohackingher" ], "worksFor": { "@type": "Organization", "name": "BodyHackGuide", "url": "https://www.bodyhackguide.co" } }, "publisher": { "@type": "Organization", "name": "BodyHackGuide", "url": "https://www.bodyhackguide.co" }, "mainContentOfPage": { "@type": "WebPageElement", "cssSelector": "main" }, "about": { "@type": "Drug", "name": "Sunifiram (DM-235)", "alternateName": [ "DM-235", "DM 235", "1-(4-benzoylpiperazin-1-yl)propan-1-one", "1-benzoyl-4-propanoylpiperazine" ], "description": "Sunifiram, also called DM-235, is a piperazine that came out of an academic medicinal chemistry program at the University of Florence, not out of a pharmaceutical company. It was first reported in 2000 as one of a series of acylpiperazines obtained by simplifying a bicyclic scaffold, and it stood out for potency: it prevented amnesia in the mouse passive avoidance test at doses about a thousand times lower than piracetam-like reference compounds (PMID: 11087574; PMID: 12070754). Despite the racetam-style name it is not a pyrrolidinone and is not structurally a racetam. The mechanism is not fully resolved. Binding studies found no affinity for the major central receptors or channels, yet sunifiram prevented amnesia induced by drugs acting on several different transmitter systems, including scopolamine, mecamylamine, baclofen and clonidine (PMID: 12070754; PMID: 16834757). Two glutamatergic actions have been documented. Sunifiram and its analog unifiram reversed amnesia induced by the AMPA receptor antagonist NBQX in mice and reversed kynurenic acid blockade of NMDA-mediated noradrenaline release in rat hippocampal slices, an effect abolished by NBQX (PMID: 14600801). Separately, in mouse hippocampal slices sunifiram enhanced long-term potentiation with a bell-shaped concentration-response curve peaking at 10 nanomolar; the enhancement was blocked by an antagonist of the glycine site of the NMDA receptor but not by an antagonist of the polyamine site, and involved protein kinase C alpha, Src family kinase and calcium/calmodulin-dependent protein kinase II (PMID: 23733502). Sunifiram also increased acetylcholine release in rat brain (PMID: 11087574). In disease-model animals, sunifiram improved spatial reference memory in the Y maze and short-term memory in novel object recognition in olfactory bulbectomized mice and restored hippocampal long-term potentiation, with those effects blocked by a glycine site inhibitor; it did not improve depressive behavior in the same animals (PMID: 23295391). There is no human data of any kind. No clinical trial, case series or pharmacokinetic study has been published, and searches of ClinicalTrials.gov return no records. The chemist who led the group that discovered sunifiram and unifiram wrote in 2015 that he had discovered by chance that dozens of websites were selling both compounds as cognitive enhancers for healthy people, even though only a few preclinical studies had been performed and their long-term toxicity was unknown, and that neither compound had been protected by a patent or taken forward by industry (PMID: 25831025). Sunifiram is not approved in any country, is not a controlled substance in the United States and has no established human dose, safety threshold or contraindication list. Everything sold is a research chemical. One frequently cited paper on sunifiram carbamate hybrids as dual acetylcholinesterase inhibitors and NMDA co-agonists was retracted by the journal in 2026 (PMID: 42565552), so any claim traced back to it should be treated as unsupported.", "activeIngredient": "Sunifiram (DM-235)", "administrationRoute": "Oral", "mechanismOfAction": "Sunifiram has no established single target and shows no affinity for the major central receptors or channels in binding assays, yet it prevents amnesia induced through cholinergic, nicotinic, GABAergic and adrenergic manipulations (PMID: 12070754; PMID: 16834757). The clearest documented actions are glutamatergic. In mice it reversed amnesia caused by the AMPA receptor antagonist NBQX, and in rat hippocampal slices it reversed kynurenic acid antagonism of NMDA-mediated noradrenaline release, an effect abolished by NBQX, which implicates AMPA-mediated transmission (PMID: 14600801). In mouse hippocampal slices it enhanced long-term potentiation with a bell-shaped concentration-response relationship peaking at 10 nanomolar; the effect was blocked by 7-chlorokynurenic acid at the glycine site of the NMDA receptor and involved protein kinase C alpha, Src family kinase and CaMKII (PMID: 23733502). It also increased acetylcholine release in rat brain (PMID: 11087574).", "dosageForm": "capsule", "legalStatus": "Not approved for human use — research chemical", "warning": "For research purposes only. Not for human consumption." } }, { "@context": "https://schema.org", "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "What is Sunifiram (DM-235) used for in research?", "acceptedAnswer": { "@type": "Answer", "text": "Sunifiram, also called DM-235, is a piperazine that came out of an academic medicinal chemistry program at the University of Florence, not out of a pharmaceutical company. It was first reported in 2000 as one of a series of acylpiperazines obtained by simplifying a bicyclic scaffold, and it stood out for potency: it prevented amnesia in the mouse passive avoidance test at doses about a thousand times lower than piracetam-like reference compounds (PMID: 11087574; PMID: 12070754). Despite the racetam-style name it is not a pyrrolidinone and is not structurally a racetam. The mechanism is not fully resolved. Binding studies found no affinity for the major central receptors or channels, yet sunifiram prevented amnesia induced by drugs acting on several different transmitter systems, including scopolamine, mecamylamine, baclofen and clonidine (PMID: 12070754; PMID: 16834757). Two glutamatergic actions have been documented. Sunifiram and its analog unifiram reversed amnesia induced by the AMPA receptor antagonist NBQX in mice and reversed kynurenic acid blockade of NMDA-mediated noradrenaline release in rat hippocampal slices, an effect abolished by NBQX (PMID: 14600801). Separately, in mouse hippocampal slices sunifiram enhanced long-term potentiation with a bell-shaped concentration-response curve peaking at 10 nanomolar; the enhancement was blocked by an antagonist of the glycine site of the NMDA receptor but not by an antagonist of the polyamine site, and involved protein kinase C alpha, Src family kinase and calcium/calmodulin-dependent protein kinase II (PMID: 23733502). Sunifiram also increased acetylcholine release in rat brain (PMID: 11087574). In disease-model animals, sunifiram improved spatial reference memory in the Y maze and short-term memory in novel object recognition in olfactory bulbectomized mice and restored hippocampal long-term potentiation, with those effects blocked by a glycine site inhibitor; it did not improve depressive behavior in the same animals (PMID: 23295391). There is no human data of any kind. No clinical trial, case series or pharmacokinetic study has been published, and searches of ClinicalTrials.gov return no records. The chemist who led the group that discovered sunifiram and unifiram wrote in 2015 that he had discovered by chance that dozens of websites were selling both compounds as cognitive enhancers for healthy people, even though only a few preclinical studies had been performed and their long-term toxicity was unknown, and that neither compound had been protected by a patent or taken forward by industry (PMID: 25831025). Sunifiram is not approved in any country, is not a controlled substance in the United States and has no established human dose, safety threshold or contraindication list. Everything sold is a research chemical. One frequently cited paper on sunifiram carbamate hybrids as dual acetylcholinesterase inhibitors and NMDA co-agonists was retracted by the journal in 2026 (PMID: 42565552), so any claim traced back to it should be treated as unsupported." } }, { "@type": "Question", "name": "What forms does Sunifiram (DM-235) come in?", "acceptedAnswer": { "@type": "Answer", "text": "Sunifiram (DM-235) is available in capsule form." } }, { "@type": "Question", "name": "How much does Sunifiram (DM-235) cost?", "acceptedAnswer": { "@type": "Answer", "text": "Prices start at $59.99 across 1 verified vendor." } }, { "@type": "Question", "name": "How do I compare Sunifiram (DM-235) vendors?", "acceptedAnswer": { "@type": "Answer", "text": "Compare prices, payment methods, shipping, and COA scores across 1 vendor." } } ] }, { "@context": "https://schema.org", "@type": "Organization", "@id": "https://www.bodyhackguide.co#organization", "name": "BodyHackGuide", "alternateName": "BHG", "url": "https://www.bodyhackguide.co", "logo": { "@type": "ImageObject", "url": "https://www.bodyhackguide.co/logo.png", "width": 512, "height": 512 }, "description": "Evidence-based research reference for peptides and nootropics. 124+ compound profiles, interactive dosing calculators, real-time vendor pricing, and trust-scored vendor reviews scored on a public, reproducible methodology applied to every vendor. BodyHackGuide and BHG Labs share common ownership, and we earn a commission on purchases through our links.", "foundingDate": "2024", "founder": { "@id": "https://www.bodyhackguide.co/about#person" }, "sameAs": [ "https://x.com/bodyhackguide", "https://reddit.com/r/BodyHackGuide", "https://reddit.com/r/BrainHackGuide", "https://reddit.com/r/Biohackingher", "https://discord.gg/Mhq5UdRYBA" ], "knowsAbout": [ "Peptide research", "Nootropic research", "Biohacking", "Compound dosing", "Vendor transparency" ], "publishingPrinciples": "https://www.bodyhackguide.co/editorial-standards", "ethicsPolicy": "https://www.bodyhackguide.co/editorial-standards", "diversityPolicy": "https://www.bodyhackguide.co/editorial-standards" } ] --- [Skip to content](#main-content) ## Research Use Only This site is an **educational resource** for research compounds. We do **not endorse** human consumption of any compound. BodyHackGuide and **BHG Labs share common ownership**; we rank every vendor on the same public methodology, and we earn a commission on purchases through our links. By entering, you confirm you are **21 years of age or older** and agree to our [Terms](/terms) & [Privacy Policy](/privacy). I'm 21+ — Enter SiteLeave site [![BodyHackGuide](/assets/bodyhackguide-logo-DOzZNUyh.webp)BodyHackGuide ](/) [Compare](/compare)[Wiki](/wiki)[Vendors](/vendors)[Deals](/deals)[Stacks](/stack-builder)[Nootropics](/nootropics)[Tools](/tools) Learn Community Search ⌘K [Sign In](/auth?returnTo=%2Fcompound%2Fsunifiram) 100K+ researchers trust BodyHackGuide — Join [r/BodyHackGuide](https://reddit.com/r/bodyhackguide) 1. [Home](/) 2. [Compounds](/compare) 3. Sunifiram (DM-235) ![Disguised Alpha logo](https://disguisedalpha.com/wp-content/themes/assets/logos/disguised-logo-2x.png) Best price right now $0.10/mg · $59.99 for 600mg at Disguised Alpha [Buy at Disguised Alpha](https://www.bodyhackguide.co/go/disguised-alpha?utm_source=compound-sticky-bar&utm_campaign=b5a01155-4996-4a80-a06e-3fd4d2c53f32&utm_medium=best-price-cta) [Where to buy Sunifiram (DM-235)](/buy/sunifiram) [Sunifiram (DM-235) coupon codes](/coupons/sunifiram) [Sunifiram (DM-235) protocol](/protocol/sunifiram) [Alternatives to Sunifiram (DM-235)](/alternatives-to/sunifiram) [Sunifiram (DM-235) side effects](/side-effects/sunifiram) 1. [Home](/) 3. [Compounds](/compare) 5. Sunifiram (DM-235) ![Sunifiram (DM-235) molecular structure](/assets/peptide-structure-placeholder-DUmZBF_j.png) # Sunifiram (DM-235) Nootropics Preclinical Download PDF Also known as: DM-235, DM 235, 1-(4-benzoylpiperazin-1-yl)propan-1-one, 1-benzoyl-4-propanoylpiperazine Sunifiram, also called DM-235, is a piperazine that came out of an academic medicinal chemistry program at the University of Florence, not out of a pharmaceutical company. It was first reported in 2000 as one of a series of acylpiperazines obtained by simplifying a bicyclic scaffold, and it stood out for potency: it prevented amnesia in the mouse passive avoidance test at doses about a thousand times lower than piracetam-like reference compounds (PMID: 11087574; PMID: 12070754). Half-Life: Not established. No pharmacokinetic study in humans or animals has been published, and the group that discovered the compound stated that its long-term toxicity was unknown (PMID: 25831025). Route: Oral MW: 246.30 g/mol CAS: 314728-85-3 Last reviewed: Sep 7, 2026 [ Nootropics Category ](/wiki#cat-nootropics) Preclinical Research Stage OverviewChemical InfoDosing & ProtocolsInteractionsResearchCompare Prices1 Related ## Overview ### Best Price Available ![Disguised Alpha logo](https://disguisedalpha.com/wp-content/themes/assets/logos/disguised-logo-2x.png) Disguised Alpha $59.99 60 capsules (10 mg) · capsule [Buy Now](https://disguisedalpha.com/product/sunifram/?coupon=reddit) Compare 1 vendor ### At A Glance Mechanism Sunifiram has no established single target and shows no affinity for the major central receptors or channels in binding assays, yet it prevents amnesia induced through cholinergic, nicotinic, GABAergic and adrenergic manipulations (PMID: 12070754; PMID: 16834757). The clearest do… Half-Life Not established. No pharmacokinetic study in humans or animals has been published, and the group that discovered the compound stated that its long-term toxicity was unknown (PMID: 25831025). Routes Oral Potential Benefits Prevented scopolamine-induced amnesia in the passive avoidance test in mice at doses about a thousand times lower than piracetam-like reference compounds (PMID: 12070754) Prevented scopolamine-induced memory impairment in the Morris water maze in rats without impairing motor coordination or spontaneous motility (PMID: 12070754) Reversed amnesia induced by the AMPA receptor antagonist NBQX in mice (PMID: 14600801) Enhanced hippocampal long-term potentiation through the glycine site of the NMDA receptor in mouse hippocampal slices, with a bell-shaped concentration-response curve (PMID: 23733502) Improved Y maze and novel object recognition performance and restored hippocampal long-term potentiation in olfactory bulbectomized mice (PMID: 23295391) ### Overview Sunifiram, also called DM-235, is a piperazine that came out of an academic medicinal chemistry program at the University of Florence, not out of a pharmaceutical company. It was first reported in 2000 as one of a series of acylpiperazines obtained by simplifying a bicyclic scaffold, and it stood out for potency: it prevented amnesia in the mouse passive avoidance test at doses about a thousand times lower than piracetam-like reference compounds (PMID: 11087574; PMID: 12070754). Despite the racetam-style name it is not a pyrrolidinone and is not structurally a racetam. The mechanism is not fully resolved. Binding studies found no affinity for the major central receptors or channels, yet sunifiram prevented amnesia induced by drugs acting on several different transmitter systems, including scopolamine, mecamylamine, baclofen and clonidine (PMID: 12070754; PMID: 16834757). Two glutamatergic actions have been documented. Sunifiram and its analog unifiram reversed amnesia induced by the AMPA receptor antagonist NBQX in mice and reversed kynurenic acid blockade of NMDA-mediated noradrenaline release in rat hippocampal slices, an effect abolished by NBQX (PMID: 14600801). Separately, in mouse hippocampal slices sunifiram enhanced long-term potentiation with a bell-shaped concentration-response curve peaking at 10 nanomolar; the enhancement was blocked by an antagonist of the glycine site of the NMDA receptor but not by an antagonist of the polyamine site, and involved protein kinase C alpha, Src family kinase and calcium/calmodulin-dependent protein kinase II (PMID: 23733502). Sunifiram also increased acetylcholine release in rat brain (PMID: 11087574). In disease-model animals, sunifiram improved spatial reference memory in the Y maze and short-term memory in novel object recognition in olfactory bulbectomized mice and restored hippocampal long-term potentiation, with those effects blocked by a glycine site inhibitor; it did not improve depressive behavior in the same animals (PMID: 23295391). There is no human data of any kind. No clinical trial, case series or pharmacokinetic study has been published, and searches of ClinicalTrials.gov return no records. The chemist who led the group that discovered sunifiram and unifiram wrote in 2015 that he had discovered by chance that dozens of websites were selling both compounds as cognitive enhancers for healthy people, even though only a few preclinical studies had been performed and their long-term toxicity was unknown, and that neither compound had been protected by a patent or taken forward by industry (PMID: 25831025). Sunifiram is not approved in any country, is not a controlled substance in the United States and has no established human dose, safety threshold or contraindication list. Everything sold is a research chemical. One frequently cited paper on sunifiram carbamate hybrids as dual acetylcholinesterase inhibitors and NMDA co-agonists was retracted by the journal in 2026 (PMID: 42565552), so any claim traced back to it should be treated as unsupported. ### Potential Research Fields Cognitive enhancement NMDA glycine site AMPA receptor pharmacology Nootropics ## Chemical Information IUPAC Name Not yet available CAS Number 314728-85-3 Molecular Formula C14H18N2O2 Molecular Mass 246.30 g/mol ![Sunifiram (DM-235) molecular structure](https://pubchem.ncbi.nlm.nih.gov/rest/pug/compound/cid/4223812/PNG) [View on PubChem](https://pubchem.ncbi.nlm.nih.gov/compound/4223812) ## Dosing & Protocols ### Unlock Dosing Protocols Free account gets you: - View beginner, intermediate & advanced protocols - See weight-based dosing calculations - Access cycle length & frequency data [Create free account](/auth)[Sign in](/auth) 2,800+ researchers already in ## Research ### Unlock Research Data Free account gets you: - Browse PubMed study summaries - See clinical trial phases & results - Access mechanism of action details [Create free account](/auth)[Sign in](/auth) 2,800+ researchers already in ## Interactions ### Contraindications None established, because no human study exists. Mechanism-based cautions: sunifiram acts at the glycine site of the NMDA receptor and enhances long-term potentiation with a bell-shaped concentration-response curve in mouse hippocampal slices, so higher exposure is not simply more of the same effect (PMID: 23733502). Compounds that increase NMDA and AMPA receptor signaling carry a theoretical excitotoxicity and seizure risk, which is relevant to anyone with a seizure disorder or recent brain injury. No reproductive toxicity, genotoxicity, repeat-dose toxicity or drug interaction data have been published in any species. Research Disclaimer This interaction data is compiled from published research and community reports. It may not be exhaustive. Always consult a healthcare professional before combining compounds. Best Price $59.99 Best $/mg $0.1000 Vendors 1 Listings 1 capsule [Sign in for alerts ](/auth) Form Allcapsule Sort Price $/mg Vendor Vendor Product Form Qty Price $/mg Coupon ![Disguised Alpha logo](https://disguisedalpha.com/wp-content/themes/assets/logos/disguised-logo-2x.png) [Disguised Alpha](/vendor/disguised-alpha) [50 ](/vendor-trust-scorecard) 🇺🇸 US 🇪🇺 EU 🇬🇧 UK Sunifiram 10 mg capsules (60) capsule 60 capsules (10 mg) ● In Stock $59.99 BEST $0.100 — [Buy](https://disguisedalpha.com/product/sunifram/?coupon=reddit) Get Sunifiram (DM-235) Price Drop Alerts Set a target price and we'll notify you when any vendor drops below it. Current lowest: $59.99 [Sign in to set alerts](/auth) ### Sign in to leave a review Reviews on BodyHackGuide are tied to verified user accounts and moderated before publishing. Sign in (free, no spam) to share your experience with Sunifiram (DM-235). [Sign in](/auth) Current low $59.99 as of Sep 7, 2026 7-day low $59.99 30-day low $59.99 30-day change — baseline building Tracking since Sep 7, 2026 · 1 data point ### Vendors Selling Sunifiram (DM-235) [ ![Disguised Alpha logo](https://disguisedalpha.com/wp-content/themes/assets/logos/disguised-logo-2x.png) #### Disguised Alpha 1 listing · from $59.99 ](/vendor/disguised-alpha) How we score these vendors Every supplier above is graded 0–100 on COA verification, payment transparency, shipping, reviews, and active listings. Methodology published, no pay-to-rank. [View Scorecard](/vendors/scorecard) ### Related Compounds [View All](/wiki) [ ### 9-Me-BC (9-Methyl-β-carboline) Nootropics Preclinical 9-Methyl--carboline (9-Me-BC) is a synthetic -carboline alkaloid that has drawn nootropic-community interest for a preclinical property that is genuinely unusual among -carbolines: in rodent and cell-culture studies it appears to stimulate the dopaminergic phenotype - raising tyrosine hydroxylase, the number of differentiated dopamine neurons and dopamine content - while also showing neuroprotective, neurorestorative and anti-inflammatory effects, plus in-vitro MAO-A/MAO-B inhibition \[PMID:17913302, PMID:20374418, PMID:32285253\]. t½ Not characterized in humans (no pharmacokinetic data). Community/anecdotal only: ~5-25 mg per day, oral. No validated or approved human dose exists. 6 studies View Profile ](/compound/9-mbc)[ ### Aniracetam Nootropics Approved (Italy) Aniracetam is a pyrrolidinone in the racetam family, developed by Hoffmann-La Roche under the code Ro 13-5057. t½ About half an hour for the parent drug in humans. Plasma elimination half-life was 0.47 to 0.49 hours after a single 400 mg oral dose in 20 healthy male volunteers (PMID: 19025058). Aniracetam is extensively metabolized to N-anisoyl-GABA and anisic acid; in six elderly hospitalized patients with cerebrovascular disease and reduced creatinine clearance, metabolite half-life was 4 to 7 times longer than in young volunteers (PMID: 9062694). Preclinical View Profile ](/compound/aniracetam)[ ### Bemethyl (bemitil) Nootropics Approved (Russia) Bemethyl, known in the Russian literature as bemitil and sold in the region under names including Metaprot, Bemactor and Antihot, is 2-ethylthiobenzimidazole, normally handled as the hydrobromide salt. t½ Not established in humans; in healthy volunteers given a single 250 mg oral dose of the Metaprot capsule form, peak serum ethylthiobenzimidazole averaged 0.91 microg/mL at about 1.06 h, and no terminal half-life was reported (PMID: 21870773) Preclinical View Profile ](/compound/bemethyl)[ ### Bromantane Nootropics Russia Approved Bromantane is an atypical psychostimulant and anxiolytic developed in the 1980s at the Zakusov Institute of Pharmacology of the Russian Academy of Medical Sciences, originally created as an adaptogen for Soviet military and elite athletic use and later approved in Russia for the treatment of neurasthenic and asthenic disorders under the trade name Ladasten. 34 studies View Profile ](/compound/bromantane)[ ### Cyclazodone Nootropics Preclinical Cyclazodone is the N-cyclopropyl derivative of pemoline, a 4-oxazolidinone stimulant. Preclinical View Profile ](/compound/cyclazodone)[ ### Dihexa Nootropics Preclinical Dihexa is a synthetic peptide analogue of the angiotensin IV metabolite LVV-hemorphin-7, developed at Washington State University. t½ Not characterized in humans. Dihexa was engineered for metabolic stability (resistant to plasma and enzymatic degradation) and blood-brain-barrier penetration; in preclinical work its central procognitive effects appear to outlast its plasma presence. 5 to 40 mg oral per day (anecdotal range; no established human dose) 1 studies View Profile ](/compound/dihexa) [ View Full Dosage Guide → Protocols, calculator & safety for Sunifiram (DM-235) ](/guides/dosage/sunifiram) ### Best Price ![Disguised Alpha logo](https://disguisedalpha.com/wp-content/themes/assets/logos/disguised-logo-2x.png) Disguised Alpha $59.99 [Buy Now](https://disguisedalpha.com/product/sunifram/?coupon=reddit) 1 vendors · 1 listings ### Research Score 30 0 PubMed studies ### Quality Indicators Data Completeness 63% Description Mechanism of Action Chemical Data Dosing Protocols Safety Profile PubMed Studies Interactions Vendor Listings ### Quick Facts Half-Life Not established. No pharmacokinetic study in humans or animals has been published, and the group that discovered the compound stated that its long-term toxicity was unknown (PMID: 25831025). Molecular Weight 246.30 g/mol Administration Oral CAS Number 314728-85-3 Trial Phase Preclinical 0 [Full Dosage Guide](/guides/dosage/sunifiram)[Calculate Your Dose](/tools/reconstitution) Research Disclaimer This information is for educational and research purposes only. Not intended as medical advice. Consult a healthcare professional before use. ## Frequently Asked Questions What is Sunifiram (DM-235) used for in research? Sunifiram, also called DM-235, is a piperazine that came out of an academic medicinal chemistry program at the University of Florence, not out of a pharmaceutical company. It was first reported in 2000 as one of a series of acylpiperazines obtained by simplifying a bicyclic scaffold, and it stood out for potency: it prevented amnesia in the mouse passive avoidance test at doses about a thousand times lower than piracetam-like reference compounds (PMID: 11087574; PMID: 12070754). Despite the racetam-style name it is not a pyrrolidinone and is not structurally a racetam. The mechanism is not fully resolved. Binding studies found no affinity for the major central receptors or channels, yet sunifiram prevented amnesia induced by drugs acting on several different transmitter systems, including scopolamine, mecamylamine, baclofen and clonidine (PMID: 12070754; PMID: 16834757). Two glutamatergic actions have been documented. Sunifiram and its analog unifiram reversed amnesia induced by the AMPA receptor antagonist NBQX in mice and reversed kynurenic acid blockade of NMDA-mediated noradrenaline release in rat hippocampal slices, an effect abolished by NBQX (PMID: 14600801). Separately, in mouse hippocampal slices sunifiram enhanced long-term potentiation with a bell-shaped concentration-response curve peaking at 10 nanomolar; the enhancement was blocked by an antagonist of the glycine site of the NMDA receptor but not by an antagonist of the polyamine site, and involved protein kinase C alpha, Src family kinase and calcium/calmodulin-dependent protein kinase II (PMID: 23733502). Sunifiram also increased acetylcholine release in rat brain (PMID: 11087574). In disease-model animals, sunifiram improved spatial reference memory in the Y maze and short-term memory in novel object recognition in olfactory bulbectomized mice and restored hippocampal long-term potentiation, with those effects blocked by a glycine site inhibitor; it did not improve depressive behavior in the same animals (PMID: 23295391). There is no human data of any kind. No clinical trial, case series or pharmacokinetic study has been published, and searches of ClinicalTrials.gov return no records. The chemist who led the group that discovered sunifiram and unifiram wrote in 2015 that he had discovered by chance that dozens of websites were selling both compounds as cognitive enhancers for healthy people, even though only a few preclinical studies had been performed and their long-term toxicity was unknown, and that neither compound had been protected by a patent or taken forward by industry (PMID: 25831025). Sunifiram is not approved in any country, is not a controlled substance in the United States and has no established human dose, safety threshold or contraindication list. Everything sold is a research chemical. One frequently cited paper on sunifiram carbamate hybrids as dual acetylcholinesterase inhibitors and NMDA co-agonists was retracted by the journal in 2026 (PMID: 42565552), so any claim traced back to it should be treated as unsupported. What forms does Sunifiram (DM-235) come in? Sunifiram (DM-235) is available in capsule form. How much does Sunifiram (DM-235) cost? Prices start at $59.99 across 1 verified vendor. How do I compare Sunifiram (DM-235) vendors? Compare prices, payment methods, shipping, and COA scores across 1 vendor. ## Research Tools [ ### Peptide Calculator Reconstitution & syringe units ](/tools/reconstitution)[ ### Reconstitution Guide How to mix, step by step ](/guides/how-to-reconstitute-peptides)[ ### Nasal Spray Calc mL per actuation ](/tools/intranasal)[ ### Half-Life Visualizer Decay curves ](/tools/halflife) ## Related Compounds [View All](/wiki) [ ### 9-Me-BC (9-Methyl-β-carboline) Nootropics Preclinical 9-Methyl--carboline (9-Me-BC) is a synthetic -carboline alkaloid that has drawn nootropic-community interest for a preclinical property that is genuinely unusual among -carbolines: in rodent and cell-culture studies it appears to stimulate the dopaminergic phenotype - raising tyrosine hydroxylase, the number of differentiated dopamine neurons and dopamine content - while also showing neuroprotective, neurorestorative and anti-inflammatory effects, plus in-vitro MAO-A/MAO-B inhibition \[PMID:17913302, PMID:20374418, PMID:32285253\]. t½ Not characterized in humans (no pharmacokinetic data). Community/anecdotal only: ~5-25 mg per day, oral. No validated or approved human dose exists. 6 studies View Profile ](/compound/9-mbc)[ ### Aniracetam Nootropics Approved (Italy) Aniracetam is a pyrrolidinone in the racetam family, developed by Hoffmann-La Roche under the code Ro 13-5057. t½ About half an hour for the parent drug in humans. Plasma elimination half-life was 0.47 to 0.49 hours after a single 400 mg oral dose in 20 healthy male volunteers (PMID: 19025058). Aniracetam is extensively metabolized to N-anisoyl-GABA and anisic acid; in six elderly hospitalized patients with cerebrovascular disease and reduced creatinine clearance, metabolite half-life was 4 to 7 times longer than in young volunteers (PMID: 9062694). Preclinical View Profile ](/compound/aniracetam)[ ### Bemethyl (bemitil) Nootropics Approved (Russia) Bemethyl, known in the Russian literature as bemitil and sold in the region under names including Metaprot, Bemactor and Antihot, is 2-ethylthiobenzimidazole, normally handled as the hydrobromide salt. t½ Not established in humans; in healthy volunteers given a single 250 mg oral dose of the Metaprot capsule form, peak serum ethylthiobenzimidazole averaged 0.91 microg/mL at about 1.06 h, and no terminal half-life was reported (PMID: 21870773) Preclinical View Profile ](/compound/bemethyl)[ ### Bromantane Nootropics Russia Approved Bromantane is an atypical psychostimulant and anxiolytic developed in the 1980s at the Zakusov Institute of Pharmacology of the Russian Academy of Medical Sciences, originally created as an adaptogen for Soviet military and elite athletic use and later approved in Russia for the treatment of neurasthenic and asthenic disorders under the trade name Ladasten. 34 studies View Profile ](/compound/bromantane)[ ### Cyclazodone Nootropics Preclinical Cyclazodone is the N-cyclopropyl derivative of pemoline, a 4-oxazolidinone stimulant. Preclinical View Profile ](/compound/cyclazodone)[ ### Dihexa Nootropics Preclinical Dihexa is a synthetic peptide analogue of the angiotensin IV metabolite LVV-hemorphin-7, developed at Washington State University. t½ Not characterized in humans. Dihexa was engineered for metabolic stability (resistant to plasma and enzymatic degradation) and blood-brain-barrier penetration; in preclinical work its central procognitive effects appear to outlast its plasma presence. 5 to 40 mg oral per day (anecdotal range; no established human dose) 1 studies View Profile ](/compound/dihexa) Free 2026 Peptide Cheat Sheet — 50 pages, PDF Reconstitution math, concentration charts, half-lives, and vendor trust tiers. The reference we wish we had on day one. [Download Free](/guides/peptide-cheat-sheet-download?utm_source=compound-sunifiram) ### Need bloodwork before starting? Full hormone + metabolic panels from Anabolic Insights. Code CHONCH for first-order discount. [Order Bloodwork](https://anabolicinsights.ai/?ref=nwm2zjb) ![BodyHackGuide](/assets/bodyhackguide-logo-DOzZNUyh.webp) ### BodyHackGuide Your biohacking research hub — compound pricing, brain health protocols, dosing tools, and vendor reviews. [support@bodyhackguide.co](mailto:support@bodyhackguide.co) [](https://discord.gg/Mhq5UdRYBA)[](https://reddit.com/r/BodyHackGuide)[](https://x.com/bodyhackguide) Explore #### Explore - [Compare prices](/compare) - [Research suppliers](/vendors) - [Deals](/deals) - [Coupons](/coupons) - [Nootropics](/nootropics) - [Brain health](/brain-health) - [Blog](/blog) - [Guides](/guides) Tools #### Tools - [Reconstitution](/tools/reconstitution) - [Dosage calculator](/tools/dosage) - [Half-life visualizer](/tools/halflife) - [COA lookup](/tools/coa) - [Cost calculator](/tools/cost-calculator) - [Stack builder](/stack-builder) - [All tools →](/tools) Trust & vendors #### Trust & vendors - [Vendor directory](/vendors) - [Trust scorecard](/vendors/scorecard) - [Get BHG verified](/vendors/get-vetted) - [Scoring methodology](/vendors/methodology) - [Peptide cheatsheet](/guides/peptide-cheat-sheet-download) Company #### Company - [About](/about) - [Affiliate disclosure](/affiliate-disclosure) - [Editorial standards](/editorial-standards) - [Creators](/creators) - [Coaches](/coaches) - [Privacy](/privacy) - [Terms](/terms) - [Full site directory →](/site-directory) **Ownership & Affiliate Disclosure:** BodyHackGuide and BHG Labs share common ownership. We rank every vendor on the same public, reproducible [methodology](/vendors/methodology), and we earn a commission from purchases made through our links at no extra cost to you. Full details in our [affiliate disclosure](/affiliate-disclosure). **Research Disclaimer:** All compounds listed are for laboratory and research purposes only. Not for human consumption. This site does not sell, distribute, or promote any products. Always consult a qualified healthcare professional and comply with local regulations. © 2026 BodyHackGuide. All rights reserved. · [Terms](/terms) · [Privacy](/privacy) hi 👋